Metraipolis › archive › dc_fe79571b77d6

TunR2, a novel mode-of-action tunicamycin-type antibiotic: Pharmacokinetics in C57BL/6 mouse and Holstein cattle — Europe PMC PMID:40700378

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40700378
DOI
10.1371/journal.pone.0327932
License (as archived)
CC0-1.0
Archived
2026-10-06T09:44:51.424Z
SHA-256 of the archived text
bae5bde3c79e23fee9cb8530716f853bfa5e2d40cfeb69b56c04f76a59e6df3a
Stable URL of this page
https://metraipolis.com/documento/dc_fe79571b77d6

How to cite

TunR2, a novel mode-of-action tunicamycin-type antibiotic: Pharmacokinetics in C57BL/6 mouse and Holstein cattle — Europe PMC PMID:40700378 — Europe PMC (en), https://europepmc.org/article/MED/40700378 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_fe79571b77d6 (Metraipolis archive dc_fe79571b77d6, sha256 bae5bde3c79e23fee9cb8530716f853bfa5e2d40cfeb69b56c04f76a59e6df3a)
BibTeX
@misc{dcfe79571b77d6,
  title = {TunR2, a novel mode-of-action tunicamycin-type antibiotic: Pharmacokinetics in C57BL/6 mouse and Holstein cattle — Europe PMC PMID:40700378},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40700378},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_fe79571b77d6; sha256 bae5bde3c79e23fee9cb8530716f853bfa5e2d40cfeb69b56c04f76a59e6df3a},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40700378. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

We have investigated the pharmacokinetics of TunR2, a modified tunicamycin-type antibiotic, in mice and cattle. TunR2 has previously been shown to be effective in a mycobacterial disease model using zebrafish, with a minimal activation of the eukaryotic unfolded protein response (upr) and a reduction in the in vivo mycobacterial burden. In this study, we presented statistically relevant pharmacokinetics of native tunicamycin (Tun) and two less toxic modified analogs, TunR2 and TunR1, using a well-defined clonal C57BL/6 mouse (both male and female). Blood samples were collected at multiple time points, and plasma concentrations were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were calculated using a two-compartment analysis. Our findings indicate that Tun and TunR1 tend to distribute in tissue compared to TunR2, which has a longer half-life than Tun. This translates into longer TunR2 activity time, potentially allowing for less frequent dosing than Tun or TunR1. We subsequently administered the modified TunR2 to Holstein cattle using a three-bolus intravenous regimen. We monitored blood, milk, urine, and feces over 90 days. In dairy cattle, the pharmacokinetics of TunR2 appear to be cumulative, and clear after 10 days. These findings provide critical new insights into the pharmacokinetics of TunR2. We concluded that TunR2 has considerable potential for treating bacterial infections, particularly as an antimicrobial adjuvant with well-established β-lactam antibiotics. Further studies are required to study safety and optimize dosing regimens for effective therapeutic use, as well as in combination with other antibiotics, such as β-lactams.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-07-23).
Identificativi: PMID 40700378 · PMCID PMC12286339 · DOI 10.1371/journal.pone.0327932.
Descrittori MeSH principali: Tunicamycin; Anti-Bacterial Agents.
Pagina: https://europepmc.org/article/MED/40700378 — https://doi.org/10.1371/journal.pone.0327932. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T09:43:20.304Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.